Stockscreener 앱 받기
13.95
3.72%
0.50
시장 영업 전:
13.95
전일 마감가:
$13.45
열려 있는:
$14.26
하루 거래량:
1.14M
Relative Volume:
2.30
시가총액:
$258.25M
수익:
$59,000
순이익/손실:
$-78.26M
주가수익비율:
-2.2882
EPS:
-6.0964
순현금흐름:
$-51.46M
1주 성능:
-4.97%
1개월 성능:
-17.24%
6개월 성능:
+20.78%
1년 성능:
+63.35%
1일 변동 폭
$13.49
$14.79
1주일 범위
$13.07
$15.25
52주 변동 폭
$3.39
$20.72
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
13.95 | 258.25M | 59,000 | -78.26M | -51.46M | -6.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Guggenheim | Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-05 | 개시 | TD Cowen | Buy |
| 2025-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Analysis Recap: Is Avalo Therapeutics Inc in a bullish channel2026 Setups & Momentum Based Trading Ideas - baoquankhu1.vn
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Avalo Therapeutics price target to $40 on trial confidence - Investing.com
AVTX: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Avalo Therapeutics 2025 Financial Review - AlphaStreet
Is Avalo Therapeutics Inc a potential multi bagger2026 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX St - GuruFocus
Avalo Therapeutics (NASDAQ:AVTX) Earns Buy Rating from BTIG Research - MarketBeat
Mizuho Securities Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $39 - Moomoo
AVTX: BTIG Reiterates Buy Rating with $40 Price Target | AVTX Stock News - GuruFocus
BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Avalo Therapeutics stock maintains Buy rating at BTIG ahead of trial - Investing.com
Key facts: Avalo Therapeutics posts $78.3M 2025 loss; Q4 EPS -$1.13 - TradingView
Guggenheim reiterates Buy rating on Avalo Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim reiterates Buy rating on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics Reports 2025 Financial Results and Prepares for Key Phase 2 LOTUS Trial Data of AVTX-009 in Hidradenitis Suppurativa - Minichart
Avalo Therapeutics 2025 Annual Report: Clinical Pipeline, Regulatory Risks, and Competitive Landscape - Minichart
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Avalo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avalo Therapeutics (NASDAQ:AVTX) Releases Quarterly Earnings Results, Beats Expectations By $1.17 EPS - MarketBeat
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates - The Manila Times
AVTX: 2025 saw higher R&D spending and net loss, with cash runway projected into 2028 - TradingView
Avalo 10-K: $0.0M Revenue, $78.3M Net Loss — Outlook Through 2028 - TradingView
Avalo Therapeutics (NASDAQ: AVTX) outlines HS trial plans and cash runway - Stock Titan
Avalo Therapeutics (Nasdaq: AVTX) details 2025 loss and LOTUS trial plans - Stock Titan
Avalo nears Q2 results in 250-patient skin disease drug trial - Stock Titan
Earnings Scheduled For March 23, 2026 - Sahm
If You Invested $1,000 in Avalo Therapeutics Inc (AVTX) - Stock Titan
Aug Sectors: Is Avalo Therapeutics Inc a potential multi baggerEarnings Recap Report & Real-Time Market Trend Scan - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
AVTX Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Cantor Fitzgerald L. P. Makes New $1.08 Million Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Top Executive Makes Major Move With Avalo Therapeutics Stock - TipRanks
Avalo Therapeutics chief medical officer sells $411k in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $411,695.80 in Stock - MarketBeat
Avalo Therapeutics chief medical officer sells $411k in stock - Investing.com
Avalo Therapeutics (AVTX) CMO exercises options, sells 25,492 common shares - Stock Titan
Panic Selling: Is Avalo Therapeutics Inc undervalued by DCF analysisOptions Play & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
[144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference - MarketBeat
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Can Avalo Therapeutics Inc. stock hit analyst price targets2025 Earnings Surprises & Safe Swing Trade Setups - Naître et grandir
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference - Defense World
FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):